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INTRODUCTION
Surgical repair of incisional ventral hernias is associ-
ated with considerable postoperative morbidity, risk of 
hernia recurrence, and costs.1,2 Reconstruction of ventral 
defects with primary fascial closure is suggested to lead 
to lower rates of hernia recurrences.3 To facilitate clo-
sure of the hernia defect, Ramirez et al.4 developed the 
components separation technique (CST), which implies 
a complete bilateral division of the abdominal external 
oblique aponeuroses allowing medialization of the rectus 
abdominis muscles. The traditional Ramirez technique 
is associated with large dissection surfaces as huge lipo-
cutaneous skin flaps are raised, and the rate of wound 
morbidity is considerable due to the invasiveness of the 
technique.5 Minimally invasive CST has been described as 
a promising concept for reduction of the rate of wound-
associated complications.6 However, recurrence rates after 
CST combined with mesh insertion for repair of giant in-
cisional hernias are still 4–32%.7 Iatrogenic deep muscle 
injury under CST is suggested to additionally result in lat-
eral abdominal weakness, predisposing the patient to lat-
eral herniation.8 A pharmacological safe, temporary, and 
reversible alternative to CST rather than a surgical perma-
nent division of aponeurotic tissue would thus seem clini-
cally attractive.
The lateral abdominal muscles (external abdominal 
oblique, internal abdominal oblique, and transversus ab-
dominis) partly insert through the rectus sheath in the 
linea alba. Muscle contractions by the lateral abdominal 
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Background: Repair of large incisional hernias remains a surgical and costly chal-
lenge. Temporary paralysis of the lateral abdominal wall muscles with topical ad-
ministration of botulinum toxin A (BTA) is a new therapeutic concept, which may 
obviate the need for component separation technique (CST) for repair of large 
incisional hernias. Current literature on the administration of BTA as adjunct to 
surgical repair of abdominal incisional hernias was investigated.
Methods: The electronic databases PubMed and Embase were searched for eligible 
studies. Two independent investigators evaluated the literature. Data were sought 
regarding primary fascial closure with and without CST, safety, hernia recurrence, 
method of application, and preoperative radiological imaging.
Results: Six cohort studies including a total of 133 patients receiving BTA were 
identified. No randomized or case–control studies were found. In total, 83.5% of 
the patients achieved primary fascial closure. Supplemental CST was necessary in 
24.1% of the patients. Two patients developed hernia recurrence during follow-
up. No postoperative complications or adverse events were considered related to 
the administration of BTA, except for impairment of postoperative coughing and 
sneezing. Additionally, radiological imaging showed that BTA increased the length 
of lateral abdominal muscles before surgery.
Conclusions: Preoperative administration of BTA increases muscle length and may 
facilitate primary fascial closure. Optimal administration is at least 2 weeks before re-
pair, whereas the optimal dose of BTA remains to be defined. Carefully designed ran-
domized controlled trials are warranted to identify patients who would benefit from 
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muscles exert a lateral force vector on this tendinous 
tissue, which is the reason why insufficient healing of 
a midline wound may result in hernia progression, and 
recreation of the midline may become challenging for 
the surgeon.
Botulinum toxin A (BTA) is a neurotoxic protein pro-
duced by Clostridium botulinum. BTA binds to glycopro-
teins in the cholinergic nerve terminal, blocking signal 
transmission temporarily in both motoric and autonomic 
innervations. The toxin has an advantageous safety profile 
when applied in small doses to local tissue remote from 
vital muscles and organs. The paralyzing effect reaches 
a maximum 2 weeks after topical administration and de-
clines gradually after 2.5 months.9
Animal studies have shown that preoperative paraly-
sis of the lateral abdominal muscles from intramuscu-
lar administration of BTA reduces the intraabdominal 
pressure,10 allowing closure of a hernia defect under 
less muscular tension.11 Ideally, temporary paralysis of 
the abdominal wall muscles with BTA prior to hernia re-
pair may allow primary fascial closure without the need 
for CST.
This systematic review investigates the current clinical 
evidence for administration of BTA as an adjunct to sur-
gical repair of abdominal incisional hernias in terms of 
efficacy, safety, and long-term results. Additionally, results 
of radiological imaging and application methods will be 
addressed.
METHODS
Eligibility Criteria
The study questions were conducted according to the 
population, intervention, comparison, outcome criteria.12 
The study population was patients undergoing incisional 
hernia repair. The intervention was administration of BTA 
as an adjunct to surgical hernia repair. If possible, a com-
parison was undertaken between the intervention group 
and a control group within the study. The primary outcome 
was the efficacy of BTA in relation to abdominal repair, and 
secondary outcomes were safety and long-term results.
Search and Sources
The search was conducted in PubMed and Embase in 
July 2016. All types of published human clinical studies 
were included. Publication language was limited to Eng-
lish, Spanish, and Scandinavian. These databases were sub-
ject to a similar search strategy with the following string:
(“Botulinum Toxins, Type A”[Mesh] OR “Clostridium 
botulinum type A”[Mesh] OR “Botulinum Toxins”[Mesh] 
OR bta OR btx OR btxa OR onabotulinum OR onabotu-
linumtoxin OR onabotulinumtoxina OR botox OR bot-
ulinum OR “chemical components separation”) AND 
(“Hernia”[Mesh] OR “Incisional Hernia”[Mesh] OR “Her-
nia, Umbilical”[Mesh] OR “Hernia, Ventral”[Mesh] OR 
“Hernia, Abdominal”[Mesh] OR “abdominal defect” OR 
“abdominal defects” OR hernia OR hernias OR herniation).
Study Selection and Extraction of Data
Articles were identified, screened, reported, and in-
cluded in accordance with the Preferred Reporting Items 
for Systematic Reviews and Meta-Analysis guidelines13 
(Fig. 1). Two investigators (S.S. and F.H.) independently 
screened all records based on title and abstract, and po-
tentially relevant papers were then full-text screened for 
inclusion. Studies suspected of repeatedly reporting on 
the same patient population were discussed with the au-
thors. Only the most recent publication was included, 
if patients were reported on in more than 1 publication 
(Fig. 1). Two investigators (S.S. and F.H.) reviewed refer-
ence lists of primary articles for relevant additional papers 
based on their title.
Demographic data of the included study populations 
are presented in Table 1. The primary outcome was the 
rate of primary fascial closure. The secondary outcomes 
were safety and long-term results. The following data were 
extracted from the included studies: preoperative trans-
verse diameter of the hernia defect, timing of BTA ad-
ministration before repair and the need for supplemental 
CST, adverse events related to BTA, postoperative compli-
cations, follow-up time, hernia recurrence, and mortal-
ity (Tables 2 and 3). Furthermore, radiological data were 
sought to compare defect measures before and after the 
preoperative administration of BTA. Authors of reference 
publications were contacted to obtain missing data.
Evaluation of Evidence
The quality of evidence of the included cohort stud-
ies was determined according to the Scottish Intercol-
legiate Guidelines Network,14 a validated methodology 
checklist for evaluation of the risk of bias according to 
selection, assessment, confounding, and statistical analy-
sis. CST performed as an adjunct procedure was con-
sidered a confounder for the operative hernia closure 
rate, rendering a study vulnerable to a high risk of bias. 
Additionally, follow-up time could affect the reporting 
of hernia recurrence, as studies of short follow-up times 
underestimate the recurrence rate, exposing studies for 
lead-time bias.15
Fig. 1. Flow diagram outlining selection of studies.
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RESULTS
The search strategy identified a total of 214 articles 
(Fig. 1). We excluded 37 articles due to duplicate publica-
tions across databases and 160 articles based on an irrel-
evant abstract. Additional 11 articles were excluded after 
full-text review, as they did not meet the eligibility criteria 
or repeatedly reported on the same study population. Six 
papers thus remained for further investigation.16–21
BTA Application
BTA was administered through 316,17 or 518–21 injection 
sites on each side of the abdomen. The administered total 
doses were 100 U18,21, 300 U16,17, and 500 U19,20. Four stud-
ies reported that BTA was diluted with 0.9% saline before 
administration to the following final concentrations: 2 
U/ml16,17, 50 U/ml21, or 100 U/ml19. The BTA dilution 
was then divided into 616,17 to 1018–21 equal doses. Ultraso-
nographic16,17 or electromyographic19–21 guidance allowed 
identification of the 3 muscle layers (external abdominal 
oblique, internal abdominal oblique, and transversus ab-
dominis) at the 316,17 to 518–21 planned injection sites on 
each side of the abdomen. The BTA dilution was equally 
administrated into each of the 3 muscle layers at each 
injection site, resulting in a total of 916,17 to 1518–21 distri-
Table 1.  Study Characteristics
Study Country Year Study Design N
Mean Age (y) 
(SD or Range)
Sex 
(M:F)
No. Previous 
Repairs
Total Dose 
of BTA Surgical Technique
Elstner et al.16 Australia 2016 Prospective 32 58 (36–84) 17:15 1–7 300 U Laparoscopic or  
laparoscopic-assisted open 
with mesh
Zendejas et al.17* United States 2013 Retrospective 22 62 (11) 13:9 Mean of 1.7 300 U Open or laparoscopic with 
mesh
López et al.18 Mexico 2015 Retrospective 36 52 (19–84) 15:21 — 100 U‡ Rives-Stoppa, mesh tech-
nique or simple closure
Ibarra-Hurtado et al.19 Mexico 2013 Prospective 17 35 (12) 17:0 0 500 U Rives-Stoppa mesh tech-
nique or simple closure
Ibarra-Hurtado et al.20 Mexico 2009 Prospective 12 34 (13) 12:0 — 500 U Simple closure
Cháves-Tostado et al.21 Mexico 2014 Retrospective 14 58 5:9 4 Patients 
had previ-
ous repairs
100 U Onlay, retromuscular, under-
lay or sandwich mesh 
technique
Total    133  79:54    
— Signifies not reported.
*Compared with a control group of 66 undergoing hernia repair without BTA.
‡Received from author.
Table 2. Efficacy of BTA
Study
Mean Transverse 
Defect Size, cm  
(SD or Range)
Timing of BTA  
Administration Before 
Repair
Primary Fascial 
Closure (%)
Primary Fascial 
Closure Rate without 
CST (%)
Primary Fascial  
Closure Rate with CST 
(%)
Elstner et al.16 12.3 (5–24) 1–4 wk 32 (100) 26 (81.3) 6 (18.7)
Zendejas et al.17 * Median 6 d 9 (40.9) 5 (22.7) 4 (18.2)
López et al.18 (10–15) 4 wk 31 (86.1) 27 (75.0) 4 (11.1)
Ibarra-Hurtado et al.19 14.7 (2.18) 4 wk 17 (100) 8 (47.1) 9 (52.9)
Ibarra-Hurtado et al.20 13.9 (1.49) 4 wk 12 (100) 6 (50.0) 6 (50.0)
Cháves-Tostado et al.21 17.6 (7.35) Mean 40 d 10 (71.4) 7 (50.0) 3 (21.4)
Calculated total   111 (83.5) 79 (59.4) 32 (24.1)
*Transverse defect size not reported, mean defect size was 59.7 cm2.
Table 3.  Safety and Long-Term Results
Study
Mean Follow- 
Up Time (mo)
Adverse Events Related to Administration 
of BTA
Complications 
Related to Surgery n
Mortality During 
Follow-Up
Recurrence, 
n
Elstner et al.16 19.0
Abdominal distension, impaired cough-
ing, and sneezing —  0 0
Zendejas et al.17 15.6 None Wound related 2 0 2
Other 7
López et al.18 18.0 Abdominal distension Wound related 8 0 0
Other 1
Ibarra-Hurtado et al.19 49.0 None Wound related 7 0 0
Ibarra-Hurtado et al.20 7.3 None Wound related 2 0 0
Cháves-Tostado et al.21 15.0 — Wound related 2 0 0
Other 2
Total     0 2
  Wound    21   
  Other    10   
Wound-related complications included seromas, enterocutaneus fistulas, hematomas, and surgical-site infections. Other complications included cardiovascular, 
urologic, and gastrointestinal events.
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butions on each side of the abdomen. A total of 133 pa-
tients had undergone administration of BTA16–21 followed 
by incisional hernia repair ranging from 6 days17 to more 
than 4 weeks later16,18–21 (Table 2). Figure 2 illustrates the 
technique of BTA injection under ultrasonographic guid-
ance as described by Zendejas et al.17 None of the studies 
reported on the logistics of the procedure and who per-
formed the injections.
Efficacy
The transverse mean defect size of the fascial defects 
ranged from 12.3 to 17.6 cm. Primary fascial closure was 
achieved in 79 patients (59.4%) without the need for adju-
vant CST. Supplementary CST was required in 32 patients 
(24.1%) for facilitation of fascial closure (Table 2), result-
ing in a total of 111 patients (83.5%) achieving successful 
primary fascial closure.
Elstner et al.16 reported 32 patients, of which 23 and 9 
patients presented with midline and lateral hernia defects, 
respectively. A total dose of 300 U of BTA was applied 1–4 
weeks before scheduled laparoscopic or laparoscopic-as-
sisted open hernia repair with mesh implantation. A to-
tal of 26 patients (81%) achieved primary fascial closure 
with the application of BTA, whereas 6 patients (19%) re-
quired additional unilateral or bilateral endoscopic CST 
with division of the external oblique.
Zendejas et al.17 administered BTA (total dose of 300 
U) in 22 patients a median of 6 days (range, 1–19 days) be-
fore hernia mesh repair and matched them with a control 
group of 66 patients based on age, sex, body mass index, 
history of hernia recurrence, and type of repair. There 
were no significant differences in patient demographics 
including the hernia grade between the 2 groups. All but 
one patient in the intervention group presented with a 
midline defect. In total, successful fascial closure was 
achieved in 9 patients (41%) in the BTA group and 24 pa-
tients (36%) in the control group (P = 0.3). Five patients 
(8%) in the control group and 4 patients (18%) in the 
BTA group additionally required CST (P = 0.2), resulting 
in a 23% primary fascial closure rate exclusively with the 
administration of BTA.
López et al.18 reported 36 patients undergoing BTA 
(total dose of 100 U) 4 weeks before repair of large ven-
tral hernia defects of unknown location ranging between 
10 and 15 cm in transverse size. Surgical repairs were per-
formed with retromuscular mesh repair, Sandwich-tech-
nique, or simple closure with onlay mesh. Primary fascial 
closure was obtained in 27 patients (75%) without CST as 
an adjunct procedure. Five and 4 patients required sack 
plicature and supplemental CST, respectively, resulting in 
a total of 31 (86%) achieving primary fascial closure.
Ibarra-Hurtado et al.19,20 published 2 studies including 
a total of 29 patients with midline defects who received a 
total dose of 500 U BTA 4 weeks before the hernia repair. 
Surgical repair was done with retromuscular mesh repair 
or simple suture closure without mesh. Successful primary 
fascial closure was achieved in all patients. However, 15 
patients (53%19 and 50%20) required additional CST for 
abdominal closure.
Chávez-Tostado et al.21 reported 14 patients receiving a 
total of 100 U BTA, 40 days (mean) before hernia repair 
with onlay, retromuscular, underlay, or sandwich mesh 
technique. In this study, 10 and 4 patients presented with 
midline and lateral defects, respectively. Primary fascial 
closure was obtained in 7 patients without the require-
ment of CST. Four and 3 patients underwent sack plica-
ture and CST, respectively. Thus primary fascial closure 
was achieved in 10 patients (64%).
Fig. 2. application of botulinum toxin a. eo, the external abdominal oblique muscle; io, the internal 
abdominal oblique muscle; Ta, the transversus abdominis muscle. Reproduced from by Zendejas et al: 
“outcomes of chemical component paralysis using botulinum toxin for incisional hernia repairs” World 
J Surg. 2013;37:2830–2837 with permission from Springer.
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Safety and Long-Term Results
Adverse events after administration of BTA were re-
ported in 2 studies. Some patients experienced weaker 
sneezing and coughing or abdominal distension, which 
was diagnosed subjectively.16,18 However, no patients de-
veloped pulmonary complications. Major complications 
such as surgical site occurrences were considered unre-
lated to the preoperative administration of BTA. The 
mean follow-up across studies ranged from a mean of 
7–49 months (Table 3). In the study by Zendejas et al.17, 
2 patients (9%) in the BTA group and 6 patients (9%) in 
matched control group were reported with hernia recur-
rence after a mean follow-up of 15.6 and 18.4 months. 
The incidences of both any-type of complications and 
surgical site complications were found comparable be-
tween the groups (40% versus 28%, P = 0.29; and 9% 
versus 14%, P = 0.72, respectively).
Radiological Assessments
The effect of BTA administration was evaluated by 
radiological examinations in 4 studies with computed to-
mography.16,19–21
Elstner et al.16 compared CT scans from before BTA 
administration with preoperative post-BTA scans and de-
scribed a transverse hernia defect reduction up to 58% 
with the administration of 300 U. Similarly, both studies 
by Ibarra-Hurtado et al.19,20 showed significant reduc-
tions of the transverse hernia defect (mean decrease, 
4.79 cm; 95% confidence interval [CI], 3.63–6.31; 
P < 0.001 and 5.25 cm; 95% CI, 3.59–6.91; P < 0.001) 
secondary to administrations of 500 U of BTA. In a com-
parable study, administration of 100 U of BTA resulted 
in a small and statistically nonsignificant transverse re-
duction of the hernia defect after 4 weeks.21
The length and thickness of the 3 lateral abdominal 
muscle layers were also compared before and after BTA 
administration in 2 studies.16,19 In the study by Elstner et 
al.16, a bilateral significant 4 cm mean increase (95% CI, 
3.38–4.60; P < 0.0001) of the lateral abdominal muscle 
length was observed. Similarly, Ibarra-Hurtado et al.19 re-
ported a significant 2.4–2.6 cm elongation of the lateral 
muscles, P < 0.001. Additionally, a mean reduction of 
1.0 cm muscle thickness was observed (P < 0.001).
Level of Study Evidence
Only 1 study compared the results of the interven-
tion group with a matched control group.17 However, 
controls were not matched according to hernia size, 
which was only available for 9 patients in the BTA and 
39 patients in the control group. This may lead to a low-
quality score according to the Scottish Intercollegiate 
Guidelines Network methodology14 as hernia size has a 
confounding effect on the primary fascial closure rate. 
The rest of the included studies had a single cohort de-
sign equivalent with low-to-acceptable quality.16,18–21 All 
studies but one19 were exposed to lead-time bias, and 
Elstner et al.16 declared a conflict of interest directly re-
lated to the submitted work. However, this was consid-
ered to have no effect on the reported results.
DISCUSSION
Although only few studies on the administration of 
BTA prior to incisional hernia repair have been published 
so far, both safety of the procedure and the primary fascial 
closure rate appeared high irrespective of hernia location. 
However, CST was needed in one-third of the patients as 
an adjunct to the preoperative BTA administration,16,19,20 
which might overestimate the effect of BTA.
The current literature has sufficiently described meth-
odological aspects of the BTA administration, whereas 
details were lacking on logistics including and who per-
formed the procedures. Future studies should report all 
necessary steps of the BTA application, and international 
consensus on the procedure should be achieved through 
standard operating procedures.
In this review, it was not possible to predict which pa-
tients would require additional CST, as only 1 study re-
ported on a threshold for the indication of CST (> 18 cm 
transverse hernia diameter).16 All patients presented with 
incisional hernias exceeding 10 cm in transverse fascial de-
fect size. There were few details regarding patient demog-
raphy and hernia classification, which is a critical aspect 
concerning the reported results. Therefore, it was not 
possible to determine the appropriate indication for using 
BTA as an adjunct to the hernia repair. Furthermore, the 
included literature was heterogenic and did not compare 
differences in results between surgical techniques, making 
conclusions on type of operation impossible. A satisfac-
tory clinical effect from preoperative BTA administration 
might be limited to patients with a certain hernia size and 
type, but due to the lack of a control group in most of the 
currently published studies, the prognostic patient charac-
teristics are unknown.
The relatively high rate of patients who required sup-
plementary CST to obtain a satisfactory hernia repair rais-
es the question if administration of BTA and adjuvant CST 
result in a synergetic effect. A higher abdominal compli-
ance following BTA administration was suggested by the 
radiological demonstration of flaccid paralysis of all the 
lateral abdominal muscles. An anterior CST implies divi-
sion of the external oblique aponeurosis, leaving the in-
ternal oblique and transversus abdominis muscles intact. 
After BTA administration, these muscles elongate allowing 
primary midline closure for complex cases. Alternatively, 
the synergetic effect of BTA and CST may be limited if ad-
ministration of BTA primarily affects the released muscles. 
There are multiple techniques for CST: open traditional 
anterior, minimally invasive anterior (open perforator 
sparing or endoscopic), or transversus abdominis release. 
However, information regarding the techniques for CST 
in the current literature was scarce, precluding a clear in-
terpretation of the presented results. Thus, the potential 
clinical gain from combining BTA with CST still needs to 
be scientifically documented.
Timing and dose were essential factors for reaching an 
optimal effect of BTA. Administration of BTA a median 
of 6 days before hernia repair failed to improve clinical 
results as compared with a control group without BTA.17 
According to earlier evidence, it takes at least 2 weeks be-
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fore the paralyzing effect reaches a maximum.9 Most stud-
ies achieved significant relaxation with 300–500 U of BTA. 
Only 100 U were applied in 2 studies resulting in conflict-
ing results.18,21 Thus, the optimal total dose of BTA is still 
unclear, but seems to be at least 300 U.
The lateral abdominal muscles are also involved in the 
accessory respiration, and concern has been raised as to 
the effect of BTA on postoperative respiratory function.17 
Two studies observed BTA-related weakness in accessorial 
abdominal muscle function, as patients experienced weak-
ness of coughing and sneezing.16,18 This suggests that cau-
tion should be exercised administering BTA to patients 
with chronic respiratory dysfunction.
The most common postoperative complications of in-
cisional hernia repairs were surgical-site occurrences in-
cluding seroma, enterocutaneous fistula, hematoma, and 
surgical-site infection. These complications were in 2 stud-
ies reported as related to the surgical technique rather 
than the administration of BTA.19,20 Ventral hernia repairs 
with open CST are complex due to the wide subcutane-
ous dissection needed to raise huge skin flaps, which may 
jeopardize skin perfusion. Thus, randomized controlled 
studies are highly warranted to confirm if surgical repair 
with BTA decreases the risk of postoperative complica-
tions as compared with CST.
The evidence concerning the efficacy of BTA was consid-
ered weak, as the literature was based on small population siz-
es as well as heterogeneity concerning study design, surgical 
procedures, and methods of BTA application. Given the low 
rate of reported hernia recurrences, one may expect that the 
flaccid effect caused by BTA throughout 2.5 months allowed 
the surgical incision to heal with minimal tension, reducing 
the risk of hernia recurrence. However, due to the large sub-
set of patients undergoing CST, these results might be biased. 
Additionally, the length of follow-up was insufficient for a 
proper evaluation of hernia recurrence except for 1 study.19
Pharmacological paralysis of the lateral abdominal mus-
cles appears promising as a supplementary preoperative 
method to achieve primary fascial closure in repair of large 
ventral hernias. At present, safety, efficacy, and feasibility of 
BTA cannot be fully evaluated due to lack of controlled data 
and limited details regarding indications and contraindica-
tions. Before BTA therapy becomes more widespread as a 
preoperative therapy, comparative cohort data on indication, 
application techniques, dosing, efficacy, safety, and costs are 
required. This review sets up the stage for large randomized 
studies comparing preoperative BTA with and without CST 
to provide conclusive evidence for a formal guideline.
Sinor Soltanizadeh, MS
Center for Surgical Science
Zealand University Hospital
Lykkebaekvej 1
DK-4600 Koege
Denmark
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